Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANALOG DEVICES INCADI · Entity 591 | Director | March 11, 2026 | March 12, 2026 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANALOG DEVICES INC
Report date March 11, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | Direct | 2,325 |
Reported balance
After 2026-03-11 transaction · row 1
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 747 · Balance 2,325 F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company. |
| Comm Stock - $.16-2/3 valueSEC Table I · non-derivative | IndirectBy Spouse | 50 |
Reported balance
Holding disclosure · report date 2026-03-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 50 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual grant to non-employee director of Restricted Stock Units (RSUs) that vest 100% on the earlier of March 11, 2027 or the date of the Company's next Annual Meeting of Shareholders. Upon the vesting date, each vested RSU shall automatically convert into one (1) share of common stock of the Company.
NEOGEN CORP
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 11,834 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 9,804 · Balance 11,834 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2036-10-01 | Direct | 20,558 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 20,558 · Balance 20,558 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date February 28, 2025 · Filed March 05, 2025
Section 16 reporting ended · disclosed 2025-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 74,381 |
Ending reported balance
After 2025-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-28 · Tax withholding · Disposed 7,313 · Balance 75,330 Row 2 · 2025-03-03 · Sale · Disposed 949 · Balance 74,381 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,000 | $47.00 | $141,000.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 7 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 10,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 6 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,226 Underlying: Common Shares · 3,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 13,000 | $140.00 | $1,820,000.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,000 | $38.40 | $384,000.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,000 | $47.00 | $141,000.00 |
DisclosureSEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-006161 · form4-12212021_021203.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,226 Underlying: Common Shares · 7,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,500 | $137.54 | $1,031,550.00 |
DisclosureSEC source: 0001415889-21-006161 · form4-12212021_021203.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,500 | $47.00 | $352,500.00 |
DisclosureSEC source: 0001415889-21-006161 · form4-12212021_021203.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 7,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,726 Underlying: Common Shares · 7,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 14,500 | $135.00 | $1,957,500.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,500 | $38.40 | $288,000.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,000 | $47.00 | $329,000.00 |
DisclosureSEC source: 0001415889-21-005968 · form4-12152021_031202.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,726 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,500 | $132.50 | $596,250.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-005788 · form4-12082021_021227.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 7,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,226 Underlying: Common Shares · 5,000 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 12,500 | $130.01 | $1,625,111.25 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,500 | $38.40 | $288,000.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,000 | $47.00 | $235,000.00 |
DisclosureSEC source: 0001415889-21-005271 · form4-11172021_031149.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 5,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,226 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,500 | $127.50 | $1,211,250.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,000 | $38.40 | $192,000.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-004250 · form4-09032021_020920.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · derivative · entry 5 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 10,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,500 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · derivative · entry 4 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,726 Underlying: Common Shares · 4,500 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 14,500 | $125.00 | $1,812,500.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 3 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,000 | $38.40 | $384,000.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,500 | $47.00 | $211,500.00 |
DisclosureSEC source: 0001415889-21-004018 · form4-08192021_030831.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $106.90 | $188,999.20 |
DisclosureSEC source: 0001415889-21-002831 · form4-06072021_020648.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,782 Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 00:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,200 | $121.79 | $755,098.00 |
DisclosureSEC source: 0001415889-21-001357 · form4-03052021_040351.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,550 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 587 | $120.61 | $70,798.07 |
DisclosureSEC source: 0001415889-21-001214 · form4-03022021_040329.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,000 | $121.58 | $607,900.00 |
DisclosureSEC source: 0001415889-21-001214 · form4-03022021_040329.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,337 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 98,708 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000901 · form4-02232021_040251.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,708 Underlying: Common Shares · 98,708 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,902 on February 19, 2022, 32,903 on February 19, 2023, and 32,903 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000901 · form4-02232021_040251.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,337 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 30,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 30,000 | $107.01 | $3,210,360.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,080 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $38.40 | $1,152,000.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,650 | $102.47 | $374,031.20 |
DisclosureSEC source: 0001179110-20-009962 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,080 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.47 to $102.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,768 | $92.62 | $163,752.16 |
DisclosureSEC source: 0001179110-20-007034 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,730 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,429 | $77.89 | $111,304.81 |
DisclosureSEC source: 0001179110-20-002891 · edgar.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,498 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,788 | $79.19 | $220,781.72 |
DisclosureSEC source: 0001179110-20-002891 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,927 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 82,757 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002274 · edgar.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,757 Underlying: Common shares · 82,757 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,585 on February 21, 2021, 27,586 on February 21, 2022, and 27,586 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002274 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,715 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,120 | $88.61 | $99,244.54 |
DisclosureSEC source: 0001179110-20-001464 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,140 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.61 to $88.615, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 21:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,188 | $85.13 | $101,134.44 |
DisclosureSEC source: 0001179110-19-008064 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,260 Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 62,725 | $0.00 Strike: $76.12 | $0.00 |
DisclosureSEC source: 0001179110-19-007238 · edgar.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,725 Underlying: Common shares · 62,725 shares Expires 2029-06-02 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,908 on June 3, 2020, 20,908 on June 3, 2021, and 20,909 on June 3, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.